Meeder Asset Management’s Beam Therapeutics BEAM Stock Holding History

Meeder Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-97	Closed	-$2.69K	–	903
2025 Q4	$2.69K	Buy	+97	New	+$2.48K	﹤0.01%	851
2025 Q2	–	Sell	-64	Closed	-$1.25K	–	870
2025 Q1	$1.25K	Buy	+64	New	+$1.68K	﹤0.01%	886
2024 Q4	–	Sell	-118	Closed	-$2.89K	–	910
2024 Q3	$2.89K	Buy	+118	New	+$3.05K	﹤0.01%	804
2021 Q4	–	Sell	-2,304	Closed	-$200K	–	1280
2021 Q3	$200K	Sell	2,304 -269	-10%	-$27K	0.01%	720
2021 Q2	$331K	Buy	2,573 +1,058	+70%	+$84.3K	0.02%	617
2021 Q1	$122K	Buy	+1,515	New	+$144K	0.01%	862
2020 Q4	–	Sell	-1,375	Closed	-$34K	–	1890
2020 Q3	$34K	Buy	+1,375	New	+$34.1K	﹤0.01%	1023

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Meeder Asset Management's BEAM Position: Q1 2026 in Review

Meeder Asset Management sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 97 shares — an estimated $2.69K sold.

Meeder Asset Management first reported a position in BEAM in Q3 2020 and held it in 7 quarters. The position peaked at $331K in Q2 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

Meeder Asset Management reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
Meeder Asset Management sold 97 Beam Therapeutics shares in Q1 2026, an estimated $2.69K.
Meeder Asset Management first reported a position in Beam Therapeutics in Q3 2020 and held it in 7 quarters.
Meeder Asset Management's Beam Therapeutics position peaked at $331K in Q2 2021.
251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.